<?xml version='1.0' encoding='utf-8'?>
<rss version="2.0">
	<channel>
		<title>OOIR Trends: Clinical Medicine (Medicine, Research &amp; Experimental)</title>
		<description>Aktuelle Paper-Trends im Bereich Clinical Medicine (Medicine, Research &amp; Experimental) von OOIR (mit Titel und Metadaten von Crossref)</description>
		<link>https://ooir.org</link>
		<language>en-us</language>
		<pubDate>Wed, 27 Aug 2025 01:02:02 GMT</pubDate>
		<lastBuildDate>Wed, 27 Aug 2025 01:02:02 GMT</lastBuildDate>
		<item>
			<title>Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic health: a randomized, crossover trial</title>
			<link>https://doi.org/10.1038/s41591-025-03842-0</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 2618
Autoren: Samuel J. Dicken, Friedrich C. Jassil, Adrian Brown, Monika Kalis, Chloe Stanley, Chaniqua Ranson, Tapiwa Ruwona, Sulmaaz Qamar, Caroline Buck, Ritwika Mallik, Nausheen Hamid, Jonathan M. Bird, Alanna Brown, Benjamin Norton, Claudia A. M. Gandini Wheeler-Kingshott, Mark Hamer, Chris van Tulleken, Kevin D. Hall, Abigail Fisher, Janine Makaronidis, Rachel L. Batterham
Journal: Nature Medicine
Veröffentlicht: 2025-08-04
Abstract: Abstract
          Ultraprocessed food (UPF) consumption is associated with noncommunicable disease risk, yet no trial has assessed its health impact within the context of national dietary guidelines. In a 2 × 2 crossover randomized controlled feeding trial, 55 adults in England (body mass index ≥25 to &amp;lt;40 kg m−2, habitual UPF intake ≥50% kcal day−1) were provided with two 8-week ad libitum diets following the UK Eatwell Guide: (1) minimally processed food (MPF) and (2) UPF, in a random order. Twenty-eight people were randomized to MPF then UPF, and 27 to UPF then MPF; 50 participants comprised the intention-to-treat sample. The primary outcome was the within-participant difference in percent weight change (%WC) between diets, from baseline to week 8. Participants were blinded to the primary outcome. MPF (%WC, −2.06 (95% confidence interval (CI), −2.99, −1.13) and UPF (%WC, −1.05 (95% CI, −1.98, −0.13)) resulted in weight loss, with significantly greater %WC on MPF (Δ%WC, −1.01 (95% CI, −1.87, −0.14), P = 0.024; Cohen’s d, −0.48 (95% CI, −0.91, −0.06)). Mild gastrointestinal adverse events were common on both diets. Findings indicate greater weight loss on MPF than UPF diets and needing dietary guidance on food processing in addition to existing recommendations. Clinicaltrials.gov registration: NCT05627570.
DOI: 10.1038/s41591-025-03842-0
ISSN: 1078-8956
Tag der Erhebung (OOIR): 2025-08-27</description>
			<guid isPermaLink="false">ooir-trend-10.1038/s41591-025-03842-0-2025-08-27-1</guid>
			<pubDate>Mon, 04 Aug 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer</title>
			<link>https://doi.org/10.1126/scitranslmed.ads3085</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 1191
Autoren: Meriem Bahri, Taha Al-Adhami, Emre Demirel, Jit Sarkar, Karen T. Feehan, Joanne E. Anstee, Tik Shing Cheung, Dominika Sosnowska, Chloé A. Woodman, William Macmorland, Dorothy D. Yang, James Rosekilly, Renee Gitsaki-Taylor, Cheryl E. Gillett, Cheryl L. Scudamore, James Spicer, Khondaker Miraz Rahman, James N. Arnold
Journal: Science Translational Medicine
Veröffentlicht: 2025-08-06
Abstract: 
            A subset of perivascular tumor-associated macrophages (PvTAMs) expressing lymphatic vessel endothelial hyaluronan receptor–1 (LYVE-1) relies on heme oxygenase–1 (HO-1) activity to maintain an immunologically cold tumor microenvironment, which suppresses the efficacy of chemotherapy. Consequently, HO-1 inhibition represents a strategy to target immunosuppressive LYVE-1
            +
            PvTAMs and improve therapeutic responses. We developed and characterized KCL-HO-1i, a small-molecule, orally bioavailable HO-1 inhibitor. In chemotherapy-resistant spontaneous murine
            MMTV-PyMT
            breast cancer and subcutaneous MN/MCA1 sarcoma models, targeting the PvTAM function with KCL-HO-1i enhanced chemotherapy effects and sensitized tumors to treatment. KCL-HO-1i combined with chemotherapy promoted an immunologically hot tumor microenvironment characterized by increased infiltration of CD8
            +
            T cells exhibiting effector function. These findings identify KCL-HO-1i as a nontoxic, orally bioavailable small-molecule immunotherapeutic targeting a key subset of protumoral PvTAMs, offering a combinatorial strategy to enhance chemotherapy efficacy in cancer.
          
DOI: 10.1126/scitranslmed.ads3085
ISSN: 1946-6234
Tag der Erhebung (OOIR): 2025-08-27</description>
			<guid isPermaLink="false">ooir-trend-10.1126/scitranslmed.ads3085-2025-08-27-2</guid>
			<pubDate>Wed, 06 Aug 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results</title>
			<link>https://doi.org/10.1038/s41591-025-03876-4</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 998
Autoren: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Eileen M. O’Reilly
Journal: Nature Medicine
Veröffentlicht: 2025-08-11
Abstract: Abstract
          Cellular immunity, mediated by tumor antigen-specific CD4+ and CD8+ T cells, has a critical role in the success of cancer immunotherapy by targeting intracellular driver and passenger tumor mutations. We present the final results of the phase 1 AMPLIFY-201 trial, in which patients who completed standard locoregional treatment, with minimal residual mKRAS disease (n = 25, 20 pancreatic cancer and 5 colorectal cancer), received monotherapy vaccination with lymph node-targeting ELI-002 2P, including mutant KRAS (mKRAS) amphiphile-peptide antigens (G12D, G12R) and amphiphile-adjuvant CpG-7909. At a median follow-up of 19.7 months, efficacy correlated with mKRAS-specific T cell responses above or below a threshold 9.17-fold increase over baseline, with median radiographic relapse-free survival not reached, versus 3.02 months (hazard ratio (HR) = 0.12, P = 0.0002) and median overall survival not reached versus 15.98 months (HR = 0.23, P = 0.0099). Seventy-one percent of evaluable patients induced both CD4+ and CD8+ subsets, with sustained immunogenicity. Following ELI-002 2P treatment, antigen spreading was observed in 67% of patients, with increased T cells reactive to personalized, tumor antigens absent from the ELI-002 2P vaccine. Therefore, lymph node-targeting amphiphile vaccination induces persistent T cell responses targeting oncogenic driver KRAS mutations, alongside personalized, tumor antigen-specific T cells, which may correlate to clinical outcomes in pancreatic and colorectal cancer. ClinicalTrials.gov registration: NCT04853017.
DOI: 10.1038/s41591-025-03876-4
ISSN: 1078-8956
Tag der Erhebung (OOIR): 2025-08-27</description>
			<guid isPermaLink="false">ooir-trend-10.1038/s41591-025-03876-4-2025-08-27-3</guid>
			<pubDate>Mon, 11 Aug 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>An mRNA-based broad-spectrum antiviral inspired by ISG15 deficiency protects against viral infections in vitro and in vivo</title>
			<link>https://doi.org/10.1126/scitranslmed.adx5758</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 626
Autoren: Yemsratch T. Akalu, Roosheel S. Patel, Justin Taft, Rodrigo Canas-Arranz, Rachel Geltman, Ashley Richardson, Sofija Buta, Marta Martin-Fernandez, Christos Sazeides, Rebecca L. Pearl, Gayatri Mainkar, Andrew P. Kurland, Haylen Rosberger, Diana D. Kang, Ann Anu Kurian, Keerat Kaur, Jennie Altman, Yizhou Dong, Jeffrey R. Johnson, Lior Zangi, Jean K. Lim, Randy A. Albrecht, Adolfo García-Sastre, Brad R. Rosenberg, Dusan Bogunovic
Journal: Science Translational Medicine
Veröffentlicht: 2025-08-13
Abstract: Type I interferons (IFN-Is) are cytokines with potent antiviral and inflammatory capacities. IFN-I signaling drives the expression of thousands of IFN-I–stimulated genes (ISGs), whose aggregate function results in the control of viral infections. A few of these ISGs are tasked with negatively regulating the IFN-I response to prevent overt inflammation. ISG15 is a negative regulator whose absence leads to persistent, low-grade elevation of ISG expression and concurrent, often self-resolving, mild autoinflammation. The limited breadth and low-grade persistence of ISGs expressed in ISG15 deficiency are sufficient to confer broad-spectrum antiviral resistance. Inspired by the antiviral state of humans with ISG15 deficiency, we identified a nominal collection of 10 ISGs that recapitulated the broad antiviral potential of the IFN-I system, which typically induces the expression of thousands of ISGs. The expression of this 10-ISG collection in an IFN-I–nonresponsive cell line increased cellular resistance to Zika virus, vesicular stomatitis virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A lipid nanoparticle–encapsulated messenger RNA (mRNA) formulation of this 10-ISG collection reduced influenza A virus plaque size in samples collected from infected mice when given prophylactically. Moreover, when used collectively and delivered prophylactically, the 10-ISG collection was able to protect hamsters against a lethal SARS-CoV-2 challenge, in contrast with the lack of efficacy when mRNAs were delivered individually. These findings suggest that these 10 ISGs have potential as a broad-spectrum antiviral prophylactic.
DOI: 10.1126/scitranslmed.adx5758
ISSN: 1946-6234
Tag der Erhebung (OOIR): 2025-08-27</description>
			<guid isPermaLink="false">ooir-trend-10.1126/scitranslmed.adx5758-2025-08-27-4</guid>
			<pubDate>Wed, 13 Aug 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>AI-driven multi-omics modeling of myalgic encephalomyelitis/chronic fatigue syndrome</title>
			<link>https://doi.org/10.1038/s41591-025-03788-3</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 352
Autoren: Ruoyun Xiong, Elizabeth Aiken, Ryan Caldwell, Suzanne D. Vernon, Lina Kozhaya, Courtney Gunter, Lucinda Bateman, Derya Unutmaz, Julia Oh
Journal: Nature Medicine
Veröffentlicht: 2025-07-25
DOI: 10.1038/s41591-025-03788-3
ISSN: 1078-8956
Tag der Erhebung (OOIR): 2025-08-27</description>
			<guid isPermaLink="false">ooir-trend-10.1038/s41591-025-03788-3-2025-08-27-5</guid>
			<pubDate>Fri, 25 Jul 2025 00:00:00 GMT</pubDate>
		</item>
	</channel>
</rss>